CAR-T cell: Toxicities issues: Mechanisms and clinical management

CAR-T cells are modified T cells expressing a chimeric antigen receptor targeting a specific antigen. They have revolutionized the treatment of B cell malignancies (aggressive lymphomas, B-ALL), and this has raised hopes for application in many other pathologies (myeloma, AML, solid tumors, etc.). However, these therapies are associated with novel and specific toxicities (cytokine release syndrome and neurotoxicity). These complications, although mostly managed in a conventional hospitalization unit, can sometimes be life threatening, leading to admission of patients to the intensive care unit. Management relies mainly on anti-IL6R (tocilizumab) and corticosteroids. However, the optimal treatment regimen is still a matter of debate, and the management of the most severe forms is even less well codified. In addition to CRS and ICANS, infections, cytopenia and hypogammaglobulinemia are other frequent complications. This article reviews the mechanisms, risk factors, clinical presentation, and management of these toxicities.

Automated summary

CAR-T cells have revolutionized the treatment of B cell malignancies, but come with novel toxicities such as cytokine release syndrome and neurotoxicity. Management depends mainly on anti-IL6R and corticosteroids, but the optimal treatment regimen is still debatable. Infections, cytopenia, and hypogammaglobulinemia are other common complications besides CRS and ICANS.